Loading...
HCM logo

HUTCHMED (China) LimitedNasdaqGS:HCM Stock Report

Market Cap US$2.4b
Share Price
n/a
1Y-13.6%
7D12.7%
1D-2.2%
Portfolio Value
​
View

HUTCHMED (China) Limited

NasdaqGS:HCM Stock Report

Market Cap: US$2.4b

HUTCHMED (China) (HCM) Stock Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. More details

HCM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance2/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 61.4% below our estimate of its fair value

Earnings are forecast to grow 34.43% per year

Risk Analysis

Profit margins (3.3%) are lower than last year (77.5%)


HCM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW435,263 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
435,263 investors already sharing narratives
View all narratives

HUTCHMED (China) Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for HUTCHMED (China)
Historical stock prices
Current Share PriceUK£13.57
52 Week HighUK£18.30
52 Week LowUK£9.77
Beta0.45
1 Month Change8.13%
3 Month Change27.06%
1 Year Change-13.62%
3 Year Change-6.41%
5 Year Change-64.67%
Change since IPO0.52%

Recent News & Updates

Seeking Alpha • Jul 19

Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts

Summary Hutchmed basically combines a growing oncology franchise with late-stage immunology assets and an early ATTC pipeline. Their Fruzaqla international rollout and improving China execution could also help increase their recurring revenues. Similarly, Sovleplenib, Fanregratinib, and SAFFRON give HCM several options to further derisk its broader pipeline. HCM also has a highly liquid balance sheet and doesn’t appear excessively valued. So, I rate HCM a viable speculative “Buy” at these levels. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jul 19

Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts

Summary Hutchmed basically combines a growing oncology franchise with late-stage immunology assets and an early ATTC pipeline. Their Fruzaqla international rollout and improving China execution could also help increase their recurring revenues. Similarly, Sovleplenib, Fanregratinib, and SAFFRON give HCM several options to further derisk its broader pipeline. HCM also has a highly liquid balance sheet and doesn’t appear excessively valued. So, I rate HCM a viable speculative “Buy” at these levels. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Despite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)

Summary Despite a 32% drop in share price, HCM's oncology treatments show potential for growth, with expected revenue increases driving earnings and share price up. HCM's sale of a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million will fund internal product development, enhancing its market position. The current share price of $13.56 suggests an attractive valuation with a FWD P/E of 18.1 and an EV/Sales of 2.44. However, concerns over poor performance of the share prices of Li family-controlled companies led us to downgrade HCM from Buy to Hold. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Hutchmed Growing Sales By 64% In H1 2024

Summary Share price up nearly 20% since our previous Buy call. Approval of the colon cancer drug FRUZAQLA by the U.S. FDA was a game-changer to their growth in sales. We expect continued growth in sales of oncology products from the approval of FRUZAQLA in the E.U. and Japan. Read the full article on Seeking Alpha
Seeking Alpha • Mar 20

Hutchmed Is Turning Profitable

Summary Hutchmed China is a biopharmaceutical company with a market capitalization of $3 billion. HCM's total revenue doubled to $838 million in 2023, driven by sales of the cancer drug FRUZAQLA. The company delivered a profit of $100.8 million in 2023 and has a strong cash position of over $880 million. FDA approval at the end of last year, and hopefully similar approvals from the EU and Japan will be a gamechanger for HCM. Read the full article on Seeking Alpha

Shareholder Returns

HCMUS PharmaceuticalsUS Market
7D12.7%-1.8%0.9%
1Y-13.6%46.1%15.5%

Return vs Industry: HCM underperformed the US Pharmaceuticals industry which returned 46.1% over the past year.

Return vs Market: HCM underperformed the US Market which returned 15.5% over the past year.

Price Volatility

Is HCM's price volatile compared to industry and market?
HCM volatility
HCM Average Weekly Movement7.3%
Pharmaceuticals Industry Average Movement8.9%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: HCM has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: HCM's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20001,790Johnny Chengwww.hutch-med.com

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).

HUTCHMED (China) Limited Fundamentals Summary

How do HUTCHMED (China)'s earnings and revenue compare to its market cap?
HCM fundamental statistics
Market capUS$2.38b
Earnings (TTM)US$17.88m
Revenue (TTM)US$549.12m
133.0x
P/E Ratio
4.3x
P/S Ratio

Is HCM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HCM income statement (TTM)
RevenueUS$549.12m
Cost of RevenueUS$476.02m
Gross ProfitUS$73.10m
Other ExpensesUS$55.22m
EarningsUS$17.88m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)0.021
Gross Margin13.31%
Net Profit Margin3.26%
Debt/Equity Ratio7.4%

How did HCM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 00:17
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HUTCHMED (China) Limited is covered by 56 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
John NewmanCanaccord Genuity
Adam McCarterCavendish